Free Trial

Neogen Co. (NASDAQ:NEOG) Shares Acquired by Harbor Capital Advisors Inc.

Neogen logo with Medical background

Harbor Capital Advisors Inc. boosted its stake in shares of Neogen Co. (NASDAQ:NEOG - Free Report) by 32.1% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,303,465 shares of the company's stock after purchasing an additional 316,457 shares during the period. Neogen makes up approximately 0.7% of Harbor Capital Advisors Inc.'s portfolio, making the stock its 14th biggest holding. Harbor Capital Advisors Inc. owned 0.60% of Neogen worth $15,824,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of NEOG. Allspring Global Investments Holdings LLC raised its position in shares of Neogen by 142.6% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,982 shares of the company's stock worth $33,000 after purchasing an additional 1,165 shares during the last quarter. Headlands Technologies LLC lifted its position in shares of Neogen by 264.1% in the second quarter. Headlands Technologies LLC now owns 3,397 shares of the company's stock valued at $53,000 after acquiring an additional 2,464 shares in the last quarter. Neo Ivy Capital Management purchased a new stake in shares of Neogen during the third quarter worth approximately $66,000. Marco Investment Management LLC acquired a new position in Neogen in the 3rd quarter valued at $169,000. Finally, Raymond James Trust N.A. purchased a new position in Neogen in the 3rd quarter valued at $182,000. Hedge funds and other institutional investors own 96.73% of the company's stock.

Neogen Trading Down 5.4 %

Neogen stock traded down $0.71 during midday trading on Friday, hitting $12.36. 7,059,031 shares of the stock were exchanged, compared to its average volume of 3,064,322. The company has a current ratio of 4.41, a quick ratio of 2.79 and a debt-to-equity ratio of 0.28. The stock has a market capitalization of $2.68 billion, a price-to-earnings ratio of -112.36 and a beta of 1.23. The stock's 50-day simple moving average is $13.54 and its 200 day simple moving average is $15.11. Neogen Co. has a fifty-two week low of $11.46 and a fifty-two week high of $18.75.

Neogen (NASDAQ:NEOG - Get Free Report) last released its quarterly earnings data on Friday, January 10th. The company reported $0.11 EPS for the quarter, beating analysts' consensus estimates of ($0.01) by $0.12. Neogen had a positive return on equity of 2.80% and a negative net margin of 2.58%. The firm had revenue of $231.30 million for the quarter, compared to analysts' expectations of $227.16 million. During the same period in the prior year, the firm posted $0.11 earnings per share. The firm's quarterly revenue was up .7% on a year-over-year basis. On average, equities analysts anticipate that Neogen Co. will post 0.5 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on NEOG. StockNews.com raised shares of Neogen to a "sell" rating in a research note on Monday, September 30th. Guggenheim assumed coverage on shares of Neogen in a research note on Thursday, December 19th. They issued a "buy" rating and a $15.00 target price on the stock.

View Our Latest Stock Analysis on NEOG

Neogen Company Profile

(Free Report)

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.

Featured Articles

Institutional Ownership by Quarter for Neogen (NASDAQ:NEOG)

Should You Invest $1,000 in Neogen Right Now?

Before you consider Neogen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neogen wasn't on the list.

While Neogen currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Crypto Boom 2025: Bitcoin’s Rise and Trump’s Impact on the Market
Goldman Sachs’ 2025 Market Outlook: Top 3 Stock Picks
7 Stocks to Benefit From Trump’s Tariffs in 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines